🚀 VC round data is live in beta, check it out!
Senores Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Senores Pharmaceuticals and similar public comparables like Cellectis, Organogenesis, Greenwich LifeSciences, LENZ Therapeutics and more.
Senores Pharmaceuticals Overview
About Senores Pharmaceuticals
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
Founded
2017
HQ
Employees
194
Website
Sectors
Financials (LTM)
EV
$369M
Senores Pharmaceuticals Financials
Senores Pharmaceuticals reported last 12-month revenue of $68M and EBITDA of $20M.
In the same LTM period, Senores Pharmaceuticals generated $37M in gross profit, $20M in EBITDA, and $12M in net income.
Revenue (LTM)
Senores Pharmaceuticals P&L
In the most recent fiscal year, Senores Pharmaceuticals reported revenue of $47M and EBITDA of $12M.
Senores Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $68M | XXX | $47M | XXX | XXX | XXX |
| Gross Profit | $37M | XXX | $21M | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $20M | XXX | $12M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $12M | XXX | $6M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | — | — | $21M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Senores Pharmaceuticals Stock Performance
Senores Pharmaceuticals has current market cap of $382M, and enterprise value of $369M.
Market Cap Evolution
Senores Pharmaceuticals' stock price is $8.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $369M | $382M | -0.9% | XXX | XXX | XXX | $0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSenores Pharmaceuticals Valuation Multiples
Senores Pharmaceuticals trades at 5.4x EV/Revenue multiple, and 18.7x EV/EBITDA.
EV / Revenue (LTM)
Senores Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, Senores Pharmaceuticals has market cap of $382M and EV of $369M.
Equity research analysts estimate Senores Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Senores Pharmaceuticals has a P/E ratio of 33.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $382M | XXX | $382M | XXX | XXX | XXX |
| EV (current) | $369M | XXX | $369M | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | 18.7x | XXX | 31.9x | XXX | XXX | XXX |
| EV/EBIT | 22.1x | XXX | 40.0x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | 17.8x | XXX | XXX | XXX |
| P/E | 33.0x | XXX | 59.7x | XXX | XXX | XXX |
| EV/FCF | (31.2x) | XXX | (28.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Senores Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Senores Pharmaceuticals Margins & Growth Rates
Senores Pharmaceuticals' revenue in the last 12 month grew by 33%.
Senores Pharmaceuticals' revenue per employee in the last FY averaged $0.4M.
Senores Pharmaceuticals' rule of 40 is 62% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Senores Pharmaceuticals' rule of X is 112% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Senores Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 38% | XXX | 73% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 62% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 112% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Senores Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cellectis | XXX | XXX | XXX | XXX | XXX | XXX |
| Organogenesis | XXX | XXX | XXX | XXX | XXX | XXX |
| Greenwich LifeSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| LENZ Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Monopar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Senores Pharmaceuticals M&A Activity
Senores Pharmaceuticals acquired XXX companies to date.
Last acquisition by Senores Pharmaceuticals was on XXXXXXXX, XXXXX. Senores Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Senores Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSenores Pharmaceuticals Investment Activity
Senores Pharmaceuticals invested in XXX companies to date.
Senores Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Senores Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Senores Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Senores Pharmaceuticals
| When was Senores Pharmaceuticals founded? | Senores Pharmaceuticals was founded in 2017. |
| Where is Senores Pharmaceuticals headquartered? | Senores Pharmaceuticals is headquartered in India. |
| How many employees does Senores Pharmaceuticals have? | As of today, Senores Pharmaceuticals has over 194 employees. |
| Is Senores Pharmaceuticals publicly listed? | Yes, Senores Pharmaceuticals is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Senores Pharmaceuticals? | Senores Pharmaceuticals trades under SENORES ticker. |
| When did Senores Pharmaceuticals go public? | Senores Pharmaceuticals went public in 2024. |
| Who are competitors of Senores Pharmaceuticals? | Senores Pharmaceuticals main competitors are Cellectis, Organogenesis, Greenwich LifeSciences, LENZ Therapeutics. |
| What is the current market cap of Senores Pharmaceuticals? | Senores Pharmaceuticals' current market cap is $382M. |
| What is the current revenue of Senores Pharmaceuticals? | Senores Pharmaceuticals' last 12 months revenue is $68M. |
| What is the current revenue growth of Senores Pharmaceuticals? | Senores Pharmaceuticals revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of Senores Pharmaceuticals? | Current revenue multiple of Senores Pharmaceuticals is 5.4x. |
| Is Senores Pharmaceuticals profitable? | Yes, Senores Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Senores Pharmaceuticals? | Senores Pharmaceuticals' last 12 months EBITDA is $20M. |
| What is Senores Pharmaceuticals' EBITDA margin? | Senores Pharmaceuticals' last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Senores Pharmaceuticals? | Current EBITDA multiple of Senores Pharmaceuticals is 18.7x. |
| What is the current FCF of Senores Pharmaceuticals? | Senores Pharmaceuticals' last 12 months FCF is ($12M). |
| What is Senores Pharmaceuticals' FCF margin? | Senores Pharmaceuticals' last 12 months FCF margin is (17%). |
| What is the current EV/FCF multiple of Senores Pharmaceuticals? | Current FCF multiple of Senores Pharmaceuticals is (31.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.